ASCO 2023

ADC revolution: How can the new results be integrated…

Discussions and controversies on social-media: what is…

Sonia trial: How does the new data change clinical…

CDK4/6 inhibitors in EBC: Amazing data, but longer…

PART2: Trying to understand optimal therapy for…

PART1: How to de-escalate chemotherapy? What is the…

Data from Meta-Analyses of almost 15k Patients: Who…

Chemotherapy de-escalation in HER2+ patients:…

Chemo-immunotherapeutic signals especially in HER2low…

TILs subtypes are associated with clinical features and…

Young patients benefit from ovarian suppression

More CDK4/6 options for EBC patients

Practice changing or not quite yet?

Ribociclib has arrived in the adjuvant setting

Discussions on CDK4/6 inhibitors in EBC

Ovarian function - Ovarian suppression not necessary in…

White blood cells with increasing prognostic relevance?…

Checkpoint inhibition in endometrial cancer: new…

1/3 of patients with HER2+ in future without…

From PENELOPE-B to SURVIVE

De-escalation of CT for early BC

Early follow-up shows clear benefit

TILs in HER2+ disease - prognostic, but not enough to…

SOC of ovarian ablation confirmed in meta-analysis.

Can we preserve our patients form chemotherapy?

A challenge for clinical management

First data with adjuvant ribociclib

Tumor-informed ctDNA likely prognostic for relapse in…

TILs are prognostic but not predictive in HER2+ EBC

Analyses of ctDNA in PENELOPE-B: Test methods are…

Palbociclib after Palbociclib might not be the best…

Ribociclib improves iDFS

10 years update on ShortHER

Another proof of efficacy of immunotherapy in advanced…

My EBC highlights from ASCO23

Response adapted, chemotherapy-free option in HER2+ EBC

NATALEE nicht überraschend aber überzeugend positiv

Kolejny dowód na skuteczność immunoterapii w…

TILs sind prognostisch aber nicht prädiktiv beim HER2+…

PHERGain abre la posibilidad de evitar la quimioterapia…

Tumor-informed ctDNA wahrscheinlich prognostisch für…

Palbociclib después de Palbociclib podría no ser la…

TILs Subtypen sind assoziiert mit klinischen Merkmalen…

I miei punti salienti di ASCO23

Ovar Funktion - Ovarielle Supression verzichtbar bei…

SOC der ovarialen Ablation in der Metaanalyse bestätigt

Eine Herausforderung für das klinische Management

Response adaptierte, Chemotherapie-freie Option beim…

Von PENELOPE-B zur SURVIVE

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…

Czy wystarczy, aby zmienić standardy?

1/3 der Patientinnen mit HER2+ zukünftig ohne…

Eine Herausforderung für viele Patienten, wenig…

TILs w rakach HER2+ - znaczenie rokownicze, ale nie…

The start of precision medicine in HR+ breast cancer

Updates on ADCs in metastatic breast cancer

Molecular imaging for endocrine responsivness

E-Health Applications in Oral Cancer Therapy

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

What is the optimal therapie sequence for HR+ MBC…

Aggiornamenti sugli ADC nel carcinoma mammario…

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo…

CDK4/6i in first line and beyond & Biomarkers

The value of eHealth

Update ADC efficacy

Part 1: Important update on testosterone-recovery

ARASEC: ADT + Daralutamide for mHSPC

Reassuring real-world data!

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Confirming results for PARPi in mCRPC

Part2: Important update on testosterone-recovery

PRL-02: Intramuscular arbiraterone

PSA nadir 6 month after Radiotherapy is strong…

PAPR-inhibitors: Patient-selection matters!

Intensified or de-intensified therapy in mHSPC

AI for prediction in local prostate carcinoma

TALAPRO-2: Results and controversies

PEACE 1 - results and controversies

DEAR trial: real-world comparator analyses of ARIs

Metastasis-directed for prostate cancer

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

PSA nadir 6 månader efter radioterapi är en prognostisk…

PARP-inhibitors: La selección de pacientes es…

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Intensifierad eller de-intensifierad behandling vid…

Triple therapy in mCSPC - which is the ideal partner…

PARPi in PCa: more genetic testing is required as PRO…

Best of Bladder: ddMVC increases DFS! Standard…

Q-TWiST in the therapy of aUC

FGFR inhibition

Targeted therapies in advanced urothelial cancer: The…

Extent of lymphadenectomy in cystectomy

New SoC option for metastatic bladder cancer

New standard for MIBC

Enfortumab vedotin + pembrolizumab 1stL in…

First line in cisplatin-ineligible advance urothelial…

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El…

Best of Bladder: ddMVC increases DFS! Standard…

Primera línea en cáncer urotelial avanzado no elegible…

Update EV/Pembro, Avelumab Maintenance

The efficacy of FGFR targeting

Primary endpoint not reached: what do we learn from…

Non ccRCC: how should we treat patients today?

Long term follow up in advanced renal cell cancer: Is…

1st Line therapy RCC: which combination to choose?

New data non ccRCC

Lenvatinib + pembrolizumab in non-clear cell renal cell…

New standard for 2nd line RCC?

News from the adjuvant

Long-term follow-up for IO/TKI in mRCC

Update and take home message of 1st Line mRCC

The value of perioperative chemo-IO in rNSCLC and the…

More options in the perioperative setting

Which should we prefer: neoadjuvant, adjuvant or…

Induction options in the perioperative setting

Confirmation of neoadjuvant immunotherapy

A new standard of care for operated patients with…

ADAURA - results and controversies

ADAURA - Discussion closed?

Another neoadjuvant chemo/IO option

Perioperative treatment

Adjuvant and neoadjuvant strategies in resectable NSCLC

Adjuvant IO in KRASm patients

An imperfect analysis, but perfect results

Role of periopertative IO confirmed

A chemo-free preop. IO strategy?

Added benefit of perioperative chemo/IO in stage 2-3b…

EGFR testing necessary in the adjuvant setting

A new standard of care

OS benefit from EGFR receptor TKI

Stratégies adjuvantes et néoadjuvantes dans le CBNPC…

Toegevoegde waarde van periperatief chemo-immuno bij…

ADAURA- discussie gesloten?

Rolle der periopertativen IO bestätigt

Que devrions-nous préférer: traitement néoadjuvant,…

Un nouveau standard therapeutique pour les patients…

TTF-treatment requires further studies

Does ADC + chemo + IO replace the existing concepts?

Pembro + chemo in pts with TKI-resistant EGFRm /…

Zorifertinib: an option when osimertinib is not…

Update on KRASG12Cm treatment options - how to proceed?

TROP2-ADC shows high response rates in 1L-combination…

Stopping treatment is ok

IO in EGRF positive patients post TKI

CORRELATE - a real world analysis

ADC + ICI ± Pt-CT in patients with aNSCLC

New data from another BiTE

Treatment strategies in SCLC

Hyperfractionated radiotherapy for SCLC

A positive trial with no impact

More BiTEs, more possibilities

Más BiTEs, más posibilidades

Kunnen we biomarkers gebruiken om behandeling te…

ONCOalert (inclusive patient advocates) consensus on…

No practice-changing data in mesothelioma, other…